Barcelona-based venture capital firm investing in healthcare and life-sciences innovation. It backs early-stage biotechnology, medical-device and digital-health companies addressing unmet patient needs, including neurological therapeutics and graphene-based brain interfaces. Its funds support scientific commercialization across Spain and Europe, with a separate technology-transfer strategy financing academic spinouts and pre-seed proof-of-concept development.
Founded
2018
Type
Venture capital
Funds2
Asabys Innvierte Tech Transfer FCRE—
Life-sciences technology-transfer fund announced in May 2026 to finance academic spinouts and very early-stage biotechnology and medical-technology companies in Spain. Its planned size is up to €120 million; CDTI and EIF jointly committed €74.7 million as limited partners. It targets innovations from universities, hospitals and research centers, including AI, supercomputing, synthetic biology, new materials and therapeutic technologies. Total closed fund size remains unverified.
Sabadell Asabys Health Innovation Investments II€180M
Healthcare venture fund that reached a €180 million final close on September 26, 2024, exceeding its €150 million target. It invests in biotechnology, medical devices and digital health in Spain and Europe, with selected international investments. The final amount encompasses the second investment vehicle and its parallel structure; they are not counted as separate €180 million funds.